Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The Absorptive group had the highest serum 25 OH-Vitamin D (64.2 ± 42.1 ng/dL, p < 0.001) and serum 1,25 OH2-vitamin D (87.2 ± 65.7 pg/mL, p = 0.001).
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Parathyroid Hormone Related Peptide (PTHrP) Revisited: A Comparison of Levels in Malignant and Non-malignant Conditions
Study design awaiting verification · Calcified Tissue International · 2026
Original publication title
Parathyroid Hormone Related Peptide (PTHrP) Revisited: A Comparison of Levels in Malignant and Non-malignant Conditions
© The Author(s) 2026
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Elevated parathyroid hormone-related peptide (PTHrP) levels are often presumed to indicate malignancy-associated hypercalcemia, yet PTHrP may be elevated in nonmalignant conditions. We compared PTHrP levels in patients with known malignancies with patients with elevations of PTHrP who had defined nonmalignant diagnoses to determine which levels of PTHrP were more indicative of malignancy. A retrospective review of electronic medical records in a large midwestern hospital system was conducted using search terms hypercalcemia with elevated PTHrP (> 2.3 pmol/L (men) and > 3.4 pmol/L (women).
Binary logistic regression analyses assessed the positive predictive value (PPV, probability) of cancer. Among 236 patients with hypercalcemia and elevated PTHrP, 58 had known cancer. The others had defined nonmalignant diagnoses including primary hyperparathyroidism (n = 87), absorptive hypercalcemia (n = 28), and “other” causes (n = 63). PTHrP was highest in the cancer group (PTHrP = 36.9, 95% CI 19.8, 53.9 pmol/L, p < 0.001), however, overlap occurred. Binary logistic regression analyses showed a positive association of PTHrP levels (p < 0.001), while PTH levels were negatively associated (p < 0.001) with the presence of cancer.
When analyzed together, PTH on PTHrP had independent effects (p < 0.001). At PTH ≥ 30 pg/mL, the PPV of cancer was < 5% when PTHrP < 7.0 pmol/L and < 10% at a PTHrP < 9.0 pmol/L. In the evaluation of hypercalcemia with elevated PTHrP, simultaneous levels of PTH measurements improve estimation of cancer probability. Mild PTHrP elevations with PTH > 30 pg/mL are more consistent with nonmalignant diagnoses, although higher PTHrP levels may still warrant evaluation for occult malignancy.
Authors’ abstract
Elevated parathyroid hormone-related peptide (PTHrP) levels are often presumed to indicate malignancy-associated hypercalcemia, yet PTHrP may be elevated in nonmalignant conditions. We compared PTHrP levels in patients with known malignancies with patients with elevations of PTHrP who had defined nonmalignant diagnoses to determine which levels of PTHrP were more indicative of malignancy. A retrospective review of electronic medical records in a large midwestern hospital system was conducted using search terms hypercalcemia with elevated PTHrP (> 2.3 pmol/L (men) and > 3.4 pmol/L (women).
Binary logistic regression analyses assessed the positive predictive value (PPV, probability) of cancer. Among 236 patients with hypercalcemia and elevated PTHrP, 58 had known cancer. The others had defined nonmalignant diagnoses including primary hyperparathyroidism (n = 87), absorptive hypercalcemia (n = 28), and “other” causes (n = 63). PTHrP was highest in the cancer group (PTHrP = 36.9, 95% CI 19.8, 53.9 pmol/L, p < 0.001), however, overlap occurred. Binary logistic regression analyses showed a positive association of PTHrP levels (p < 0.001), while PTH levels were negatively associated (p < 0.001) with the presence of cancer.
When analyzed together, PTH on PTHrP had independent effects (p < 0.001). At PTH ≥ 30 pg/mL, the PPV of cancer was < 5% when PTHrP < 7.0 pmol/L and < 10% at a PTHrP < 9.0 pmol/L. In the evaluation of hypercalcemia with elevated PTHrP, simultaneous levels of PTH measurements improve estimation of cancer probability. Mild PTHrP elevations with PTH > 30 pg/mL are more consistent with nonmalignant diagnoses, although higher PTHrP levels may still warrant evaluation for occult malignancy.
Publication and source details
Original title: Parathyroid Hormone Related Peptide (PTHrP) Revisited: A Comparison of Levels in Malignant and Non-malignant Conditions
Guoyu Ling; Rukayat Akande; Stewart G. Albert
Calcified Tissue International · 2026
© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T22:20:15.390476+00:00
DOI: 10.1007/s00223-026-01552-4 · PMC13249694